| HOME >> BIOLOGY >> TECHNOLOGY |
NEW HAVEN, Conn., Feb. 4 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION) today announced that William Hahne, M.D. has joined the Company's senior management team as Vice President, Medical.
Alan Kessman, Chief Executive Officer, said, "We are extremely pleased to have Bill Hahne joining Vion in medical affairs. He has a wealth of experience in clinical development which will be extremely useful to our efforts to file a New Drug Application for Cloretazine(R) (VNP40101M) with the U.S. Food and Drug Administration in 2008."
Dr. Hahne commented, "Based on the data from two Phase II trials in elderly patients with previously untreated AML, Cloretazine(R) (VNP40101M) is an active agent in this indication. I am looking forward to working with the rest of Vion's senior management team to pursue regulatory approval for Cloretazine(R) (VNP40101M) in the United States."
Prior to joining Vion, Dr. Hahne, 54, was Vice President, Clinical Development, and then Vice President of Clinical Development and Medical Affairs of Celsion Corporation from January 2006 to December 2007. From 2003 to 2005, Dr. Hahne was Vice President of Clinical Development for CuraGen Corporation. From 1986 to 2002, Dr. Hahne worked in various positions in medical affairs for Glaxo Inc., Merrell Dow Research Institute, Marion Merrell Dow, Hoechst Marion Rousel, and Eisai, Inc. Dr. Hahne received his medical degree from Cornell University Medical College and conducted his residency in general surgery at Emory University Affiliated Hospitals in Atlanta, Georgia.
Vion Pharmaceuticals, Inc. is committed to extending the lives and
improving the quality of life of cancer patients worldwide by developing
and commercializing innovative ca
'/>"/>
| SOURCE Vion Pharmaceuticals, Inc. Copyright©2008 PR Newswire. All rights reserved |